Literature DB >> 27417951

Severe Hypertension and Bradycardia Secondary to Midodrine Overdose.

L Y Wong1, A Wong2,3,4, T Robertson5, K Burns5, M Roberts5, G K Isbister6.   

Abstract

The objective of this case is to describe the pharmacokinetics and toxicity of midodrine in overdose. A 20 year old female ingested up to 350 mg midodrine while recovering in hospital from another overdose. She developed vomiting and severe hypertension (blood pressure [BP], 210/100 mmHg). Remarkable findings included a heart rate with a range of 43-60 beats/min, spontaneous respirations (20 breaths/min), and oxygen saturations of >95 % on FiO2 25 %, and a GS of 8. She was admitted to intensive care and had a normal non-contrast CT brain. She was treated with a glyceryl trinitrate patch (5 mg) and observed for 36 h with subsequent BP reduction to 124/81 mmHg and improved in conscious state. Midodrine and desglymidodrine concentrations were measured with liquid chromatography tandem mass spectrometry and were detected with 2-h post-ingestion at concentrations of 158.4 and 169.7 ng/mL, respectively. The parent drug concentrations rapidly decreased with an elimination of half-life of 1.6 h, and the metabolite initially increased and then decreased. The peak in blood pressure appeared to coincide with peak metabolite concentrations. Midodrine in overdose can potentially cause severe hypertension and reflex bradycardia but given its short half-life treatment with vasodilator agents and supportive care is sufficient.

Entities:  

Keywords:  Antihypotensive; Orthostatic hypotension; Poisoning; Vasopressor

Mesh:

Substances:

Year:  2016        PMID: 27417951      PMCID: PMC5330956          DOI: 10.1007/s13181-016-0574-4

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  10 in total

Review 1.  Midodrine for orthostatic hypotension and recurrent reflex syncope: A systematic review.

Authors:  Ariel Izcovich; Carlos González Malla; Matias Manzotti; Hugo Norberto Catalano; Gordon Guyatt
Journal:  Neurology       Date:  2014-08-22       Impact factor: 9.910

2.  Pharmacodynamics of midodrine, an antihypotensive agent.

Authors:  P K Zachariah; D C Bloedow; T P Moyer; S G Sheps; A Schirger; R D Fealey
Journal:  Clin Pharmacol Ther       Date:  1986-05       Impact factor: 6.875

Review 3.  Hypertensive emergencies.

Authors:  C J Vaughan; N Delanty
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

4.  Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group.

Authors:  P A Low; J L Gilden; R Freeman; K N Sheng; M A McElligott
Journal:  JAMA       Date:  1997-04-02       Impact factor: 56.272

5.  Midodrine: a role in the management of neurocardiogenic syncope.

Authors:  C R Ward; J C Gray; J J Gilroy; R A Kenny
Journal:  Heart       Date:  1998-01       Impact factor: 5.994

6.  Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine.

Authors:  J Jankovic; J L Gilden; B C Hiner; H Kaufmann; D C Brown; C H Coghlan; M Rubin; F M Fouad-Tarazi
Journal:  Am J Med       Date:  1993-07       Impact factor: 4.965

7.  Midodrine in neurally mediated syncope: a double-blind, randomized, crossover study.

Authors:  Horacio Kaufmann; Daniela Saadia; Andrei Voustianiouk
Journal:  Ann Neurol       Date:  2002-09       Impact factor: 10.422

8.  Prolonged supine hypertension due to midodrine use in an orthostatic hypotensive child.

Authors:  S Olgar; R E Omeroglu
Journal:  Pediatr Cardiol       Date:  2007-05-25       Impact factor: 1.655

Review 9.  Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders.

Authors:  D McTavish; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 10.  Efficacy and safety of midodrine in the treatment of dialysis-associated hypotension.

Authors:  Mark A Perazella
Journal:  Expert Opin Drug Saf       Date:  2003-01       Impact factor: 4.250

  10 in total
  2 in total

1.  Oral Midodrine Administration During the First 24 Hours of Sepsis to Reduce the Need of Vasoactive Agents: Placebo-Controlled Feasibility Clinical Trial.

Authors:  Amos Lal; Vrinda Trivedi; Mahrukh S Rizvi; Amy Amsbaugh; Melissa K Myers; Khaled Saleh; Rahul Kashyap; Ognjen Gajic
Journal:  Crit Care Explor       Date:  2021-05-06

2.  Midodrine overdose in children: a case report and review of treatment for hypertensive emergencies.

Authors:  Meryam Jan; Elizabeth Brothers; Thomas A Nakagawa
Journal:  Transl Pediatr       Date:  2021-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.